Abstract
We studied the pharmacomodulating effects of a marine substance, bistramide D, which is capable of inducing terminal differentiation on the expression of the c-erb-B1, ras, src, myc and p53 genes in the NSCLC-N6 cell line established from a non-small cell lung carcinoma. Analysis (subsequent to treatment) demonstrated that among the genes for which it was possible to detect expression, namely c-erb-B1, c-myc and p53, only the expression of the p53 gene varied significantly. The increase of the expression rate of the p53 gene underlines its prominent role in the control of cell proliferation and differentiation.
MeSH terms
-
Antineoplastic Agents / pharmacology
-
Blotting, Northern
-
Bronchial Neoplasms / drug therapy
-
Bronchial Neoplasms / metabolism*
-
Bronchial Neoplasms / pathology*
-
Carcinoma, Non-Small-Cell Lung / drug therapy
-
Carcinoma, Non-Small-Cell Lung / metabolism*
-
Carcinoma, Non-Small-Cell Lung / pathology*
-
Cell Differentiation / drug effects
-
Cell Differentiation / physiology
-
ErbB Receptors / biosynthesis
-
ErbB Receptors / genetics
-
Ethers, Cyclic / pharmacology
-
Gene Expression Regulation, Neoplastic / drug effects
-
Genes, p53
-
Humans
-
Lung Neoplasms / drug therapy
-
Lung Neoplasms / metabolism*
-
Lung Neoplasms / pathology*
-
Oncogenes
-
Proto-Oncogene Proteins c-myc / biosynthesis
-
Proto-Oncogene Proteins c-myc / genetics
-
Proto-Oncogene Proteins pp60(c-src) / biosynthesis
-
Proto-Oncogene Proteins pp60(c-src) / genetics
-
RNA, Neoplasm / analysis
-
RNA, Neoplasm / metabolism
-
Tumor Cells, Cultured
-
Tumor Suppressor Protein p53 / biosynthesis*
-
Tumor Suppressor Protein p53 / genetics
-
ras Proteins / biosynthesis
-
ras Proteins / genetics
Substances
-
Antineoplastic Agents
-
Ethers, Cyclic
-
Proto-Oncogene Proteins c-myc
-
RNA, Neoplasm
-
Tumor Suppressor Protein p53
-
bistramide D
-
ErbB Receptors
-
Proto-Oncogene Proteins pp60(c-src)
-
ras Proteins